{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T01:08:23Z","timestamp":1770858503441,"version":"3.50.1"},"reference-count":4,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cardiovascular Revascularization Medicine"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.carrev.2025.08.015","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T09:01:33Z","timestamp":1755766893000},"page":"109-110","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Editorial: Refining the hemocompatibility paradigm in AMI-cardiogenic shock: Insights from an early Impella 5+ experience with DAPT and bivalirudin"],"prefix":"10.1016","volume":"82","author":[{"given":"Ezequiel J.","family":"Molina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.carrev.2025.08.015_bb0005","article-title":"Clinical management of the Impella 5.5 pump","volume":"S1053-2498","author":"Bernhardt","year":"2025","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.carrev.2025.08.015_bb0010","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.carrev.2025.05.003","article-title":"Hemocompatibility related complications in Impella 5+ patients treated with Bivalirudin and dual antiplatelet therapy: a SHEAR score evaluation","volume":"82","author":"Bandini","year":"2026","journal-title":"Cardiovasc Revasc Med"},{"issue":"12","key":"10.1016\/j.carrev.2025.08.015_bb0015","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1053\/j.jvca.2024.08.010","article-title":"Hemocompatibility-related adverse events in patients with temporary mechanical circulatory support: the scoring Haemostasis events and assessment for risk (SHEAR) score","volume":"38","author":"Pappalardo","year":"2024","journal-title":"J Cardiothorac Vasc Anesth"},{"issue":"10366","key":"10.1016\/j.carrev.2025.08.015_bb0020","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/S0140-6736(22)01999-7","article-title":"Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomized trial","volume":"400","author":"Li","year":"2022","journal-title":"Lancet"}],"container-title":["Cardiovascular Revascularization Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838925004531?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838925004531?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:24:47Z","timestamp":1770855887000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1553838925004531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":4,"alternative-id":["S1553838925004531"],"URL":"https:\/\/doi.org\/10.1016\/j.carrev.2025.08.015","relation":{},"ISSN":["1553-8389"],"issn-type":[{"value":"1553-8389","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Editorial: Refining the hemocompatibility paradigm in AMI-cardiogenic shock: Insights from an early Impella 5+ experience with DAPT and bivalirudin","name":"articletitle","label":"Article Title"},{"value":"Cardiovascular Revascularization Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.carrev.2025.08.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}